Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06265545
NA

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

View on ClinicalTrials.gov

Summary

To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2024-02-22

Completion Date

2026-06-30

Last Updated

2025-08-06

Healthy Volunteers

No

Interventions

DRUG

Ivosidenib,Venetoclax,gilteritinib,Selinexor

if the target gene mutations are positive, enter arm1 or arm2. other conditions, enter the chemotherapy arms (Arm3-6)

Locations (1)

Blood Hospital

Tianjin, China